Irwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants

Oct 5, 2020 • 12:21 PM EDT
5 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP(the “Company” or “Havn Life”) is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the “Board”). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer of Jamieson Laboratories (“Jamieson”), Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines. During Mr. Neufeld’s 21-year tenure with Jamieson the company went from $20 million in annual sales to over an estimated $250 million and expanded its distribution network to over 40 countries, building Jamieson to a globally recognized brand name. Mr. Neufeld is also the former President and Chief Executive Officer of Aphria Inc., a medical marijuana and cannabis oil company. Mr. Neufeld’s educational background includes a Bachelor of Economics from Western University, an Honours degree in Business from the University of Windsor and a Master of Business Administration from the University of Windsor. Mr. Neufeld is also a chartered professional accountant.

Mr. Neufeld stated, “It is clear to me that the psychedelics sector is very real and could be a catalyst of disruptive change to the health and wellness market. I believe Havn Life is uniquely positioned with the right operational team, vision and business model to establish itself as a leader in this sector, both in terms of the work it’s doing to create a leading nutraceutical wellness brand via the Havn Retail division, and in carrying out cutting-edge research and development through the Havn Labs division.”

The Company further announces that Mr. Rick Brar has been appointed as the Vice Chairman of the Board. Mr. Brar is an experienced business leader in the cannabis, nutraceutical, beverage, consumer packaged goods, agriculture, land development and construction sectors. Mr. Brar has international expertise in emerging market sectors, having incubated and grown several companies over his career. He is experienced in sales and marketing, with a track record of success in corporate sales growth, new market penetration, new product development, and long-range planning. Mr. Brar is also experienced in team building, strategic planning, new market development and the implementation of tactical sales and marketing initiatives. Mr. Brar was previously the Chief Executive Officer of Atlas Supply Company Limited, where he led one of the largest herb companies in North America for nine years. Mr. Brar was also previously the Chief Executive Officer of Zenabis Global Inc., a leading Canadian cultivator of medical and adult-use recreational cannabis and a propagator and cultivator of floral and vegetable products. Mr. Brar is currently the Chief Executive Officer & Chairman of Brains Bioceutical Corp. a global manufacturer and distributor of Cannabinoid API.

Furthermore, the Company announces the acceleration of outstanding warrants (“Accelerated Warrants”) that were issued in connection with a previous non-brokered private placement of units by the Company. Each Accelerated Warrant entitles the holder thereof to purchase one Common Share at a price of $0.50; the original exercise period of the Accelerated Warrants was 24 months, however, as a result of the Common Shares trading above $0.75 for the last 10 trading days, the exercise period has been accelerated such that it now expires within 30 days. The Company has been notified by Mr. Neufeld that he will be participating in the warrant exercise.

The Company also announces the departure of Robert Nygren as Co-head of Corporate Development and as a director of the Company, effective immediately. The Company expresses its appreciation for Robert’s services to the Company, particularly in relation to his involvement with ETC3 Holdings Ltd., a co-founder of the Company, and wishes him well in his future endeavours.

On Behalf of The Board of Directors

Susan Chapelle & Tim Moore


About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: and follow us on Facebook, Twitter and Instagram.


Investor Relations: 604 687 7130

Media: 778 238 6096

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE: Havn Life Sciences Inc.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.